Elicio Therapeutics (ELTX) Research & Development (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Research & Development came in at $6.8 million in Q1 2026, down 13.13% YoY from $7.8 million in Q1 2025, and up 33.01% on a QoQ basis from $5.1 million in Q4 2025.
Elicio Therapeutics (ELTX) Research & Development (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Research & Development data on file, last reported at $6.8 million in Q1 2026.
- Quarterly Research & Development fell 13.13% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.9 million (down 29.5% YoY) and the FY2025 annual result came in at $24.9 million, down 26.01% from the prior year.
- Research & Development climbed to $6.8 million in Q1 2026, from $5.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $11.7 million in Q1 2022 to a low of $4.3 million in Q4 2022.
- A 5-year average of $6.8 million and a median of $6.8 million in 2026 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 65.43% — and 2024, when it soared 73.93%.
- Tracing ELTX's Research & Development over 5 years: stood at $4.3 million in 2022, then soared by 43.52% to $6.2 million in 2023, then soared by 73.93% to $10.7 million in 2024, then tumbled by 52.56% to $5.1 million in 2025, then surged by 33.01% to $6.8 million in 2026.
- The last three Research & Development figures came in at $6.8 million (Q1 2026), $5.1 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | 6.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.81 Mn |
| Mar 31, 2026 | 6.76 Mn |
| Dec 31, 2025 | 5.08 Mn |
| Sep 30, 2025 | 5.04 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Mar 31, 2025 | 7.78 Mn |
| Dec 31, 2024 | 10.71 Mn |
| Sep 30, 2024 | 7.21 Mn |
| Jun 30, 2024 | 8.18 Mn |
| Mar 31, 2024 | 7.56 Mn |
| Dec 31, 2023 | 6.16 Mn |
| Sep 30, 2023 | 7.26 Mn |
| Jun 30, 2023 | 4.94 Mn |
| Mar 31, 2023 | 5.48 Mn |
| Dec 31, 2022 | 4.29 Mn |
| Sep 30, 2022 | 4.59 Mn |
| Jun 30, 2022 | 5.04 Mn |
| Mar 31, 2022 | 11.67 Mn |
| Dec 31, 2021 | 6.67 Mn |
| Sep 30, 2021 | 13.29 Mn |